Abstract
Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis (PM) performed at our center. The main endpoints were morbidity, mortality, the temperature of perfusate during HIPEC and metabolic changes throughout the procedure. Morbidity was assessed by analysis of postoperative adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0). Continuous variables of Arterial Blood Gas (ABG) analysis at three time-points were compared by the Student t test. There were no postoperative deaths. The overall grade 3–4 CTCAE complications rate at 30 days was 38.4%, with ten severe adverse events occurring to six (23.0%) patients. The temperature within HIPEC perfusion maintained between 41 and 42 °C in all cases and we experienced no HIPEC-related intraoperative complications. We observed a significant difference between all baseline and pre-HIPEC ABG parameters evaluated but no statistically significant differences between pre- and post-HIPEC ABG outcomes. This study shows that mitomycin C HIPEC-CO2 is feasible and has a safety profile comparable to that of other HIPEC techniques reported in the literature. Further research is needed to validate prospectively the safety and efficacy of this technique.
Similar content being viewed by others
Data availability
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
References
Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7:108–115
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743
Yonemura Y, Canbay E, Ishibashi H (2013) Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J 2:978394
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685
Quenet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F (2019) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis PRODIGE 7. Eur J Surg Oncol 45:e17
Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert B, Rat P (2010) Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 17:1957–1963
Sugarbaker PH, Averbach AM, Jacquet P, Stuart OA, Stephens AD (1996) Hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) with mitomycin C. Surg Technol Int 5:245–249
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42
Ceelen W (2019) HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol 45(3):400–402
Yurttas C, Fisher OM, Cortés-Guiral D, Haen SP, Königsrainer I, Königsrainer A, Beckert S, Liauw W, Löffler MW (2020) Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick? Memo 20:1–6
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surgical Oncol 18:1575–1581
Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37:2028–2040
Hompes D, D’Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V (2014) The use of oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 109:527–532
Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179:e133–e139
Silva CR, Ruiz FJ, Estévez IB, Campos JC, García AT, López MR, Poveda IG, Mata JA, Velasco SM, Santoyo JS (2017) Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study. World J Surg Oncol 15:1–8
Sánchez-García S, Villarejo-Campos P, Padilla-Valverde D, Amo-Salas M, Martín-Fernández J (2016) Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-10 Combat): a clinical pilot study. Int J Hyperthermia 32(5):488–495
Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M (2008) Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 63:389–395
Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F, Chauffert B, Rat P, Ortega-Deballon P (2015) High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery 157:72–78
Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J (2015) Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 1:10–23
Bhatt A (2018) Management of peritoneal metastases-cytoreductive surgery, HIPEC and beyond. Springer, p 79
Benoit L, Cheynel N, Ortega-Deballon P, Di Giacomo G, Chauffert B, Rat P (2008) Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surgical Oncol 15:542–546
Sánchez-García S, Padilla-Valverde D, Villarejo-Campos P, Martín-Fernández J, García-Rojo M, Rodríguez-Martínez M (2014) Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system. Surgery 155:719–725
Cianci S, Vizzielli G, Fagotti A, Pacelli F, Di Giorgio A, Tropea A, Biondi A, Scambia G (2018) A novel HIPEC technique using hybrid CO 2 recirculation system: intra-abdominal diffusion test in a porcine model. Updates Surg 70:529–533
Padilla-Valverde D, Sanchez-Garcia S, García-Santos E, Marcote-Ibañez C, Molina-Robles M, Martín-Fernández J, Villarejo-Campos P (2017) Usefulness of thermographic analysis to control temperature homogeneity in the development and implementation of a closed recirculating CO2 chemohyperthermia model. Int J Hyperthermia 33:220–226
Author information
Authors and Affiliations
Contributions
SR, FP and ADG: conceptualization. FS, RS, and ADG: methodology and validation. CA and MA: formal analysis. CA and MA: investigation. FP and MA: data curation. SR and ADG: writing—original draft preparation. SR, ADG, CA, FS, MA, and CL: writing—review and editing. All the authors have approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethics statement
This study was reviewed and approved by the Institutional Review Board of Foundation Policlinico Universitario Agostino Gemelli IRCCS. Patient consent for inclusion was obtained in all the cases.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rotolo, S., Di Giorgio, A., Santullo, F. et al. Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal metastases: analysis of short-term outcomes. Updates Surg 73, 1443–1448 (2021). https://doi.org/10.1007/s13304-021-01034-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13304-021-01034-2